I

asked a seasoned biotech business development executive, a guy who spends a lot of time digging deep into cancer drugs for potential licensing deals, what he thought about the experimental prostate cancer drug acquired by Endocyte (ECYT). Since announcing the deal on Monday morning, Endocyte’s stock price has quadrupled.

“PSMA is a target proven over and over as ineffective in treating prostate cancer due to significant off-target toxicity. Anyone looking at this can pretty much stop there,” he told me.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • A cure for any cancer would end a lot of business. Nothing to see here folks…but speculate away to only the benefit of the business leaders.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X